Rchr
J-GLOBAL ID:200901084260762629   Update date: Apr. 25, 2024

Oka Yoshihiro

岡芳弘 大阪大学 | Oka Yoshihiro
Affiliation and department:
Job title: Endowed Chair Professor
Research field  (2): Hematology and oncology ,  Immunology
Research keywords  (8): Cancer vaccine ,  CTL ,  WT1 ,  Cancer Immunotherapy ,  癌ワクチン ,  細胞障害性Tリンパ球 ,  WT1 ,  癌免疫療法
Research theme for competitive and other funds  (41):
  • 2015 - 2018 Analysis of immune response against cancer, which may lead to establishment of WT1 peptide-based immunotherapy for the conventional treatment-resistant malignancies in the respiratory medicine field
  • 2013 - 2017 Elucidation and control of molecular mechanism in WT1 peptide vaccine therapy after allogeneic hematopoietic stem cell transplantation
  • 2012 - 2015 Development of WT1 peptide-based immunotherapy for inoperable thoracic malignant tumors, and analysis of immunodynamics of the novel therapy
  • 2010 - 2012 Development of WT1 based immunotherapy after stem cell transplantation and the analysis of antitumor activity
  • 2009 - 2011 Cancer antigen WT1-targeting peptide vaccine therapy for lung cancer
Show all
Papers (199):
  • 森本 創世子, 藤木 文博, 西田 純幸, 永田 暁教, 中田 潤, 中島 博子, 尾路 祐介, 岡 芳弘, 杉山 治夫. GEM併用WT1ワクチン投与膵癌患者からのWT1^126特異的high avidity TCRの単離. 日本臨床免疫学会総会プログラム・抄録集. 2023. 51回. 121-121
  • 永田 暁教, 藤木 文博, 森本 創世子, 中田 潤, 西田 純幸, 中島 博子, 橋井 佳子, 坪井 昭博, 岡 芳弘, 尾路 祐介, et al. TCF1レポーターマウスを活用した腫瘍局所と所属リンパ節に存在する癌抗原特異的CD8+ T細胞の分類と解析. 日本がん免疫学会総会プログラム・抄録集. 2023. 27回. 122-122
  • Fumihiro Fujiki, Soyoko Morimoto, Yuya Nishida, Satoe Tanii, Nao Aoyama, Miki Inatome, Kento Inoue, Akiko Katsuhara, Hiroko Nakajima, Jun Nakata, et al. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer immunology, immunotherapy : CII. 2023. 72. 7. 2347-2356
  • Yusuke Oji, Naoki Kagawa, Hideyuki Arita, Norifumi Naka, Ken-ichiro Hamada, Hidetatsu Outani, Yasushi Shintani, Yoshito Takeda, Eiichi Morii, Kenzo Shimazu, et al. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. Cancers. 2023. 15. 2. 393-393
  • 森本 創世子, 藤木 文博, 西田 純幸, 永田 暁教, 中田 潤, 中島 博子, 尾路 祐介, 岡 芳弘, 杉山 治夫. GEM併用WT1ワクチン投与膵癌患者からのWT1^126特異的high-avidity TCRの単離. 日本臨床免疫学会総会プログラム・抄録集. 2022. 50回. 112-112
more...
MISC (195):
  • 香川尚己, 尾路祐介, 平山龍一, 木嶋教行, 岡芳弘, 杉山治夫, 貴島晴彦. Long-term outcome of a cocktail Wilms’ tumor 1 (WT1) vaccination using two HLA class I peptides and one class II peptide against recurrent malignant gliomas. 日本脳腫瘍学会学術集会プログラム・抄録集. 2023. 41st
  • Mizuki Kanegae, Naoki Kagawa, Noriyuki Kijima, Ryuichi Hirayama, Haruka Shimokado, Sumiyuki Nishida, Naoki Hosen, Akihiro Tsuboi, Yoshihiro Oka, Haruo Sugiyama, et al. Immune monitoring of malignant glioma patients treated with WT1 Trio peptide-based cancer immunotherapy. CANCER SCIENCE. 2022. 113. 524-524
  • 鐘ヶ江 瑞稀, 池島 彩香, 香川 尚己, 木嶋 教行, 平山 龍一, 下門 遥, 西田 純幸, 保仙 直毅, 坪井 昭博, 岡 芳弘, et al. 悪性神経膠腫に対するWT1ペプチドワクチン免疫療法WT1 Trioの免疫モニタリング. 日本癌学会総会記事. 2021. 80回. [P12-6]
  • アルザキ・ショーク, 王谷 英達, 鐘ヶ江 瑞稀, 下門 遥, 西田 純幸, 保仙 直毅, 坪井 昭博, 岡 芳弘, 杉山 治夫, 尾路 祐介. WT1-235ペプチドワクチンを施行された肉腫患者におけるWT1-235 IgMおよびIgG抗体. 日本癌学会総会記事. 2021. 80回. [P12-6]
  • 橋井 佳子, 岡 芳弘, 坂田 尚己, 渡辺 新, 尾路 祐介, 保仙 直毅, 山本 紘司, 服部 聡, 中島 博子, 中田 潤, et al. WT1-targeting immunotherapy after allogeneic HSCT in children with refractory acute leukemia. 日本血液学会学術集会. 2021. 83回. OS1-5
more...
Books (4):
  • WT1 peptide vaccine for the treatment of malignancies: Its development, recent progress, and future perspectives.
    Immunotherapy of Cancer, Y. Yamaguchi (ed), Springer, P159-185 2016
  • Enhancement of efficacy of Wilms’ tumor gene WT1 product-derived peptide cancer vaccine by co-administration with immunopotentiating agents: Lessons from mouse models.
    Inflammation and Immunity in Cancer, Seya T., Matsumoto M., Udaka K., Sato N. (ed), Springer, P.165-183 2015
  • Cellular and humoral immune responses against Wilms’ tumor gene WT1 product (WT1) which overexpresses in various kinds of malignant neoplasm -Toward the development of cancer vaccine targeting WT1-
    Recent Research Development in Immunology, Pandalai S.G. (ed), Research Signpost, P.97-114 2003
  • Molecular mechanisms guiding B cell development.
    Primary Immunodeficiency Disease. Oxford University Press P.55-65 1999
Lectures and oral presentations  (9):
  • WT1-CTL epitopeの同定、それをもとにしたWT1を標的としたがん免疫療法の開発、そしてその将来展望
    (第12回日本血液疾患免疫療法学会学術集会 (会長講演) 2020)
  • WT1ペプチドを用いたがんワクチン療法.
    (第13回日本組織適合性学会近畿地方会 (特別講演) 2015)
  • がん抗原ペプチドを用いたワクチン治療の原理・現況・将来展望 -WT1ペプチドがんワクチンをそのモデルとして-
    (第11回日本組織適合性学会近畿地方会(シンポジウム) 2013)
  • WT1ペプチドワクチン治療の現況.
    (日本がん免疫学会緊急シンポジウム「がんワクチン治療の現状と臨床」 2010)
  • WT1 peptide vaccine for the treatment of malignancies.
    (The 72nd Annual Meeting of the Japanese Society of Hematology (Symposium 1) 2010)
more...
Education (1):
  • - 1980 Osaka University Faculty of Medicine Medical School
Professional career (1):
  • (BLANK)
Work history (8):
  • 2017/04 - 現在 Osaka University Graduate School of Medicine Department of Cancer Stem Cell Biology Endowed Chair Professor
  • 2014/01 - 2017/03 Osaka University Graduate School of Medicine Department of Cancer Immunotherapy Specially Appointed Professor
  • 2006/01 - 2013/12 Osaka University Graduate School of Medicine Department of Respiratory Medicine, Allergy and Rheumatic Diseases Associated Professor
  • 1995/09 - 2005/12 Osaka University, the faculty of medicine Department of Medicine III Assistant Professor
  • 1992/09 - 1995/08 Basel Institute for Immunology, Basel, Switzerland Scientific Member
Show all
Committee career (4):
  • 2019/04 - 2021/03 日本血液疾患免疫療法学会 理事
  • 2015/01 - 2020/12 日本バイオセラピィ学会 評議員
  • 2010/04 - 2020/03 日本がん免疫学会 評議員
  • 2003 - 2020 日本血液学会 評議員
Association Membership(s) (7):
日本癌学会 ,  日本内科学会 ,  日本免疫学会 ,  日本血液学会 ,  日本バイオセラピィ学会 ,  日本がん免疫学会 ,  日本血液疾患免疫療法学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page